Institution · Bayer (Germany)
Most cited papers from Bayer (Germany)
Bayer (Germany)
What are the most cited papers from Bayer (Germany)?
The most cited paper from Bayer (Germany) is "Sorafenib in Advanced Hepatocellular Carcinoma" (Josep Maria Llovet et al., 2008), with 13,116 citations. Next come "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation" (9,484) and "Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles" (7,918).
Showing 50 of 60 papers. Every paper with more than 1,181 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma Josep Maria Llovet et al. · New England Journal of Medicine | 23 Jul 2008 | 13,116 |
| 2 | Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al. · New England Journal of Medicine | 10 Aug 2011 | 9,484 |
| 3 | Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles Günter Oberdörster, Eva Oberdörster, Jan Oberdörster · Environmental Health Perspectives | 22 Mar 2005 | 7,918 |
| 4 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Ann‐Lii Cheng et al. · The Lancet Oncology | 18 Dec 2008 | 5,881 |
| 5 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine | 10 Jan 2007 | 4,813 |
| 6 | Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels Helmut Blum, Hildburg Beier, Hans Joachim Gross · Electrophoresis | 1987 | 4,184 |
| 7 | BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis Scott M. Wilhelm et al. · Cancer Research | Oct 2004 | 4,060 |
| 8 | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Jordi Bruix et al. · The Lancet | 5 Dec 2016 | 3,732 |
| 9 | Poly(3,4-ethylenedioxythiophene) and Its Derivatives: Past, Present, and Future Lambertus Groenendaal, F. Jonas, Dieter Freitag et al. · Advanced Materials | Apr 2000 | 3,345 |
| 10 | A new approach to practical acute toxicity testing Dietrich Ernst Lorke · Archives of Toxicology | Dec 1983 | 3,052 |
| 11 | Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Axel F. Grothey, Eric Van Cutsem, Alberto Felice Sobrero et al. · The Lancet | 21 Nov 2012 | 2,934 |
| 12 | Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes George L. Bakris, Rajiv Agarwal, Stefan D. Anker et al. · New England Journal of Medicine | 23 Oct 2020 | 2,875 |
| 13 | Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration Jeffrey S. Heier, David M. Brown, Victor N. Chong et al. · Ophthalmology | 17 Oct 2012 | 2,522 |
| 14 | Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease John W. Eikelboom et al. · New England Journal of Medicine | 27 Aug 2017 | 2,456 |
| 15 | Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals Harry M. Olson, Graham R. Betton, Denise E. Robinson et al. · Regulatory Toxicology and Pharmacology | Aug 2000 | 2,056 |
| 16 | Vitamin C and Immune Function Anitra C. Carr, Silvia Maggini · Nutrients | 3 Nov 2017 | 2,037 |
| 17 | Refinement and Parametrization of COSMO-RS Andreas Klamt, Volker Jonas, Thorsten Bürger et al. · The Journal of Physical Chemistry A | Jun 1998 | 2,031 |
| 18 | A uniform decimal code for growth stages of crops and weeds Peter Lancashire, H. Bleiholder, T. van den Boom et al. · Annals of Applied Biology | Dec 1991 | 1,971 |
| 19 | Clinical consequences of polypharmacy in elderly Robert L. Maher, Joseph T. Hanlon, Emily R. Hajjar · Expert Opinion on Drug Safety | 27 Sep 2013 | 1,967 |
| 20 | Believe it or not: how much can we rely on published data on potential drug targets? Florian Prinz, Thomas Schlange, Khusru Asadullah · Nature Reviews Drug Discovery | 31 Aug 2011 | 1,949 |
| 21 | Rivaroxaban in Patients with a Recent Acute Coronary Syndrome Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott et al. · New England Journal of Medicine | 13 Nov 2011 | 1,902 |
| 22 | Overview of the Status and Global Strategy for Neonicotinoids Peter Jeschke, Ralf Nauen, Michael Schindler et al. · Journal of Agricultural and Food Chemistry | 21 Jun 2010 | 1,886 |
| 23 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Scott M. Wilhelm, Christopher J. Carter, Mark John Lynch et al. · Nature Reviews Drug Discovery | Oct 2006 | 1,843 |
| 24 | Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing Xinyi Guo, Yuanyuan Zhang, Liangtao Zheng et al. · Nature Medicine | 22 Jun 2018 | 1,821 |
| 25 | The genome sequence of the rice blast fungus Magnaporthe grisea Ralph A. Dean et al. · Nature | Apr 2005 | 1,707 |
| 26 | Infective Endocarditis Larry M. Baddour, Walter R. Wilson, Arnold S. Bayer et al. · Circulation | 13 Jun 2005 | 1,705 |
| 27 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet | 23 Apr 2014 | 1,665 |
| 28 | A chromosome-based draft sequence of the hexaploid bread wheat ( Triticum aestivum ) genome Klaus Mayer et al. · Science | 17 Jul 2014 | 1,651 |
| 29 | Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI Charles Michael Gibson, Roxana Mehran, Christoph Bode et al. · New England Journal of Medicine | 14 Nov 2016 | 1,595 |
| 30 | Organocatalytic cascade reactions as a new tool in total synthesis Christoph Grondal, Matthieu Jeanty, Dieter Enders · Nature Chemistry | 19 Feb 2010 | 1,583 |
| 31 | Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5 Li Liu, Yichen Cao, Charles Chen et al. · Cancer Research | 15 Dec 2006 | 1,555 |
| 32 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Scott M. Wilhelm, Lila Adnane, Philippa H. Newell et al. · Molecular Cancer Therapeutics | Oct 2008 | 1,470 |
| 33 | Repeated polyploidization of Gossypium genomes and the evolution of spinnable cotton fibres Andrew H. Paterson et al. · Nature | Dec 2012 | 1,468 |
| 34 | Scientific importance, properties and growing applications of poly(3,4-ethylenedioxythiophene) Stephan Kirchmeyer, Knud Reuter · Journal of Materials Chemistry | 2005 | 1,449 |
| 35 | Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty Bengt I. Eriksson, Lars C. Borris, Richard Joel Friedman et al. · New England Journal of Medicine | 25 Jun 2008 | 1,440 |
| 36 | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial George D. Demetri et al. · The Lancet | 21 Nov 2012 | 1,428 |
| 37 | Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension Hossein-Ardeschir Ghofrani, Andrea Maria D’Armini, Friedrich Grimminger et al. · New England Journal of Medicine | 24 Jul 2013 | 1,408 |
| 38 | IRAC: Mode of action classification and insecticide resistance management Thomas C. Sparks, Ralf Nauen · Pesticide Biochemistry and Physiology | 4 Dec 2014 | 1,385 |
| 39 | Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology | 14 Dec 2017 | 1,375 |
| 40 | A Review of Micronutrients and the Immune System–Working in Harmony to Reduce the Risk of Infection Adrian F. Gombart, Adeline Pierre, Silvia Maggini · Nutrients | 16 Jan 2020 | 1,366 |
| 41 | Riociguat for the Treatment of Pulmonary Arterial Hypertension Hossein-Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger et al. · New England Journal of Medicine | 24 Jul 2013 | 1,361 |
| 42 | Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer | 17 Dec 2010 | 1,356 |
| 43 | Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Paul W. Armstrong, Burkert Mathias Pieske, Kevin Joseph Anstrom et al. · New England Journal of Medicine | 28 Mar 2020 | 1,350 |
| 44 | Simple Selection Criteria for Drug-like Chemical Matter Ingo Muegge, Sarah L. Heald, David R. Brittelli · Journal of Medicinal Chemistry | 15 May 2001 | 1,347 |
| 45 | The Unique Role of Fluorine in the Design of Active Ingredients for Modern Crop Protection Peter Jeschke · ChemBioChem | 28 Apr 2004 | 1,343 |
| 46 | 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines Victor A. Ferraris, Jeremiah R. Brown, George John Despotis et al. · The Annals of Thoracic Surgery | 24 Feb 2011 | 1,322 |
| 47 | Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty Michael Rud Lassen, Walter Ageno, Lars C. Borris et al. · New England Journal of Medicine | 25 Jun 2008 | 1,302 |
| 48 | Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis Rajiv Agarwal, Gerasimos S Filippatos, Bertram Pitt et al. · European Heart Journal | Nov 2021 | 1,295 |
| 49 | Seed Germination and Vigor Loïc Rajjou, Manuel X. Duval, Karine Gallardo et al. · Annual Review of Plant Biology | 3 May 2012 | 1,284 |
| 50 | Insights from the genome of the biotrophic fungal plant pathogen Ustilago maydis Jörg Kämper et al. · Nature | Nov 2006 | 1,269 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.